SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. on September 13, 2024, reporting events that occurred on September 11, 2024. The filing addresses corporate governance changes and the execution of a new executive employment agreement. Note: The request metadata referenced "Streamex Corp.," but the filing text explicitly identifies the registrant as BioSig Technologies, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms and governance appointments.
Material Changes
- Board Leadership: Anthony Amato, the Company's Chief Executive Officer, was appointed as Chairman of the Board, succeeding Kenneth L. Londoner, who resigned as previously announced in February 2024.
- Executive Compensation: A new Executive Employment Agreement was entered into with Mr. Amato, effective August 1, 2024, establishing new salary and equity terms.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, market outlook, or discussion of risks and contingencies. It details the specific terms of Mr. Amato's compensation package:
- Base Salary: $300,000 annually.
- Bonus: Eligible for an annual discretionary bonus of up to 60% of the base salary.
- Stock Options: Granted 2,400,000 options at an exercise price of $0.4479 per share. 50% vested immediately; the remaining 50% vests bi-annually over 4 years.
- Restricted Stock: Granted 275,000 shares fully vested immediately and 1,275,000 shares vesting bi-annually over 3 years.
- Severance: In the event of termination without cause or for good reason, the executive is entitled to one year of base salary plus 100% of the annual bonus, immediate acceleration of equity vesting for the subsequent 12 months, and 12 months of health insurance. In a change of control scenario, severance increases to two times the sum of base salary and bonus, with 18 months of health insurance.
Investor Verification Checklist
- Verify the total dilution impact of the 3,675,000 new equity awards (options and restricted stock) granted to the CEO.
- Confirm the current outstanding share count to assess the percentage ownership represented by the new grants.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for specific performance conditions or clawback provisions not summarized in the text.
- Monitor future filings for the Company's financial performance, as this 8-K contains no operational or financial data.